This mechanism of interaction could provide an advantage in cancer cells; since the dynamics and thus concentrations of HER2 itself at the plasma membrane would not be affected, this would ensure that HER2 can continuously impose the regulatory effects on EGFR. The gene discussed is EGFR; the disease is cancer.